Gleamer raises €27 Million in series B to elevate the standard of care in radiology with AI

Cécile Hourquet


Gleamer is proud to announce a groundbreaking achievement: the successful completion of a Series B financing round, securing a remarkable €27 million in funding. This milestone marks a new chapter in Gleamer’s journey to revolutionize healthcare through cutting-edge technology.

Supernova Invest leads the funding round, accompanied by co-leader Heal Capital and the continued support of Gleamer’s long-term partners, including XAnge, Elaia, Bpi France, MACSF, UI Investissement and Crista Galli Ventures, alongside several European radiologists. With a total of €35.5 million raised to date, Gleamer is well-positioned to expand its solutions portfolio, strengthen its teams in Europe and America, and accelerate its international expansion plans.

Since its inception in 2017, Gleamer has established itself as a pioneer in AI-powered medical imaging solutions. With a comprehensive suite of clinical diagnostic solutions, Gleamer’s AI technology is certified as a Class IIa medical device under EU MDR and is partly FDA-cleared. The company’s solutions are renowned worldwide, with nine publications in major medical journals and recognition from the scientific community.

Today, Gleamer serves over 6,500 users in 650 institutions across 24 countries, processing over a million medical examinations monthly. This new funding injection will empower Gleamer to realize its strategic roadmap, deploy disruptive technological solutions at scale, and meet the evolving needs of healthcare professionals globally.

Christian Allouche, CEO and co-founder of Gleamer expressed his excitement, stating, “This new round of funding will allow us to deepen Gleamer’s mission of making AI the new standard of care in radiology. We aim to increase diagnostic accuracy and improve patient care and the efficiency of clinical practices for health professionals.”

Looking ahead, Gleamer aims to expand its portfolio of solutions to encompass CT scans and mammography, thereby covering 70% of radiologists’ routine needs. The company will accelerate its international expansion, particularly in Europe and the United States, by strengthening its sales teams and forming strategic partnerships. These partnerships will enable Gleamer’s innovative solutions to reach a broader audience and benefit countless individuals.

Rémi Spagnol, Investment Director at Supernova Invest, commented, “Gleamer is positioned as a leader in the use of AI in radiology, redefining the contours of radiology and medical imaging through disruptive technology solutions that can be deployed on a large scale.”

Gleamer’s remarkable growth and exceptional performance have earned them the title of EuroMinnies 2023 Best Vendor in Radiology, awarded by AuntMinnie Europe.

At Gleamer, we believe that AI is the new standard of care in radiology. We are grateful for the support of our investors, who share our vision for the future of healthcare. Together, we will continue pushing boundaries, driving innovation, and making a positive impact on patients’ lives worldwide.

Join us on this exciting journey as we revolutionize medical imaging with AI-powered solutions!

Related News

GLEAMER is Finalist at 2023 EuroMinnies Awards

The list of candidates for the fifth edition of the EuroMinnies Awards is now available following a high volume of nominations submitted by the members of GLEAMER is a finalist in the “Best New Radiology Vendor” category. The EuroMinnies acknowledge the top performers in European radiology, and this year’s

GLEAMER Raises € 7.5 Million to Market A.I. Platform Offering Radiologists Semi-automated Diagnosis of Medical Images

GLEAMER, a French med-tech company that develops an A.I. software platform to help radiologists diagnose their patients, announces it has secured € 7.5 million in a Series A round led by XAnge, alongside new investors MACSF, Majycc eSanté Invest, and Crista Galli

GLEAMER Publishes in the Prestigious Journal (Radiology) The Compelling Results of a Clinical Study

The combination of AI and health professionals interpretations lowered the false-negative rate (undetected fractures) on radiographs by 30% BoneView® allowed a gain in sensitivity (12% increase) and specificity (5% increase) per patient, without loss of reading speed, on exams specifically selected for their difficulty. Paris, May 18th 2021 – GLEAMER,